Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions

Neurol Neurochir Pol. 2023;57(5):444-449. doi: 10.5603/pjnns.97373. Epub 2023 Oct 27.ABSTRACTWe recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies and personal observations. Despite the promising observations, more research on larger patient groups is needed to elucidate the beneficial actions of GCs in CSF1R mutation carriers.PMID:37889001 | DOI:10.5603/pjnns.97373

Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Jaros ław Dulski E Richard Stanley Violeta Chitu Zbigniew K Wszolek Source Type: research